Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:SDGR NASDAQ:SNDX NASDAQ:YSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$27.27-2.8%$25.85$20.39▼$53.96$1.30B0.8390,964 shs422,795 shsSDGRSchrodinger$18.46-0.6%$20.17$16.60▼$28.47$1.37B1.79902,902 shs802,398 shsSNDXSyndax Pharmaceuticals$15.84+1.9%$13.04$8.58▼$22.50$1.34B0.721.88 million shs2.08 million shsYSBYS Biopharma$1.25$0.35▼$1.78$344.32M0.51172,401 shs63,510 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-2.82%-6.80%-8.58%+6.48%-43.29%SDGRSchrodinger-0.59%-5.04%-4.75%-11.59%-10.95%SNDXSyndax Pharmaceuticals+1.86%-3.00%+0.64%+64.32%-17.15%YSBYS Biopharma0.00%0.00%0.00%0.00%+531.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$27.27-2.8%$25.85$20.39▼$53.96$1.30B0.8390,964 shs422,795 shsSDGRSchrodinger$18.46-0.6%$20.17$16.60▼$28.47$1.37B1.79902,902 shs802,398 shsSNDXSyndax Pharmaceuticals$15.84+1.9%$13.04$8.58▼$22.50$1.34B0.721.88 million shs2.08 million shsYSBYS Biopharma$1.25$0.35▼$1.78$344.32M0.51172,401 shs63,510 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-2.82%-6.80%-8.58%+6.48%-43.29%SDGRSchrodinger-0.59%-5.04%-4.75%-11.59%-10.95%SNDXSyndax Pharmaceuticals+1.86%-3.00%+0.64%+64.32%-17.15%YSBYS Biopharma0.00%0.00%0.00%0.00%+531.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.40Hold$31.6015.88% UpsideSDGRSchrodinger 2.67Moderate Buy$27.8350.78% UpsideSNDXSyndax Pharmaceuticals 3.00Buy$39.22147.62% UpsideYSBYS Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest YSB, SNDX, SDGR, and AMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025SNDXSyndax PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.009/5/2025SNDXSyndax PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.009/4/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$34.008/26/2025AMPHAmphastar PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$28.00 ➝ $32.008/18/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$28.00 ➝ $19.008/15/2025SDGRSchrodingerCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $20.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/12/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$36.008/8/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$30.00 ➝ $25.008/6/2025SNDXSyndax PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$731.97M1.73$4.86 per share5.61$15.23 per share1.79SDGRSchrodinger$237.92M5.71N/AN/A$5.78 per share3.19SNDXSyndax Pharmaceuticals$23.68M57.62N/AN/A$3.38 per share4.69YSBYS Biopharma$560.76M0.00N/AN/A$1.14 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$159.52M$2.6710.218.29N/A18.64%20.76%9.68%11/5/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)YSBYS Biopharma-$21.17MN/A0.00N/AN/AN/AN/AN/AN/ALatest YSB, SNDX, SDGR, and AMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million8/4/2025Q2 2025SNDXSyndax Pharmaceuticals-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/AYSBYS BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.803.292.21SDGRSchrodingerN/A3.303.30SNDXSyndax Pharmaceuticals2.064.714.55YSBYS Biopharma0.260.940.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%SDGRSchrodinger79.05%SNDXSyndax PharmaceuticalsN/AYSBYS Biopharma52.64%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.10%SDGRSchrodinger21.00%SNDXSyndax Pharmaceuticals4.10%YSBYS BiopharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals2,02846.49 million33.90 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableSNDXSyndax Pharmaceuticals11086.14 million82.61 millionOptionableYSBYS Biopharma77393.06 millionN/ANot OptionableYSB, SNDX, SDGR, and AMPH HeadlinesRecent News About These CompaniesLakeShore Biopharma Receives Acquisition Proposal from Oceanpine CapitalAugust 19, 2025 | msn.comYS LifeOctober 25, 2024 | yourstory.comYLakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share ConsolidationOctober 3, 2024 | finanznachrichten.deLakeShore changes CEO with new executive appointmentsSeptember 5, 2024 | thepharmaletter.comTLakeShore Biopharma Co Ltd Ordinary Shares LSBAugust 17, 2024 | morningstar.comMLSB LakeShore Biopharma Co., LtdJuly 20, 2024 | seekingalpha.comPieris Pharmaceuticals (NASDAQ:PIRS) Stock Quotes, Forecast and News SummaryJuly 19, 2024 | benzinga.comYS Biopharma Co., Ltd.: YS Biopharma Announces Name Change to LakeShore BiopharmaMay 24, 2024 | finanznachrichten.deYS Biopharma Announces Name Change to LakeShore BiopharmaMay 24, 2024 | prnewswire.comYS Biopharma Co., Ltd.: YS Biopharma Announces Results of Extraordinary General MeetingMay 22, 2024 | finanznachrichten.deYS Biopharma Announces Results of Extraordinary General MeetingMay 21, 2024 | prnewswire.comYS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive OfficerMay 7, 2024 | prnewswire.comWith 80% ownership, YS Biopharma Co., Ltd. (NASDAQ:YS) insiders have a lot riding on the company's futureMay 7, 2024 | finance.yahoo.comYS Biopharma Co., Ltd.: YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleApril 29, 2024 | finanznachrichten.deYS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleApril 29, 2024 | prnewswire.comYS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call TranscriptApril 22, 2024 | finance.yahoo.comYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 19, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 19, 2024 | finanznachrichten.deYS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024April 19, 2024 | markets.businessinsider.comYS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 19, 2024 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeYSB, SNDX, SDGR, and AMPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$27.27 -0.79 (-2.82%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$27.28 +0.02 (+0.06%) As of 09/15/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Schrodinger NASDAQ:SDGR$18.46 -0.11 (-0.59%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$18.63 +0.17 (+0.92%) As of 06:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Syndax Pharmaceuticals NASDAQ:SNDX$15.84 +0.29 (+1.86%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$16.19 +0.35 (+2.21%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.YS Biopharma NASDAQ:YSBYS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
